Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

expansion stage of the trial, which will enroll a total of 46 advanced breast cancer patients overall.
  • Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic disease, 11 of 17, or almost 65% of evaluable patients in the initial cohort, achieved an objective tumor response according to RECIST criteria. These early results, which exceeded the pre-specified endpoint needed to expand the trial, compare very favorably with historical data with chemotherapy alone and are especially encouraging in this hard-to-treat cancer. Patient enrollment and dosing are continuing in the expansion stage of the trial, which will enroll a total of 49 NSCLC patients overall.
  • Completed patient enrollment in a Phase I trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. At the 2009 ASCO Annual Meeting, study researchers reported that bavituximab had demonstrated a predictable pharmacokinetic profile and acceptable safety, and that a maximum tolerated dose was not reached, even at the highest planned dose level.
  • Announced that the ASCO Research Foundation awarded one of its 2009 Career Development Awards to a researcher at the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab and chemotherapy in patients with advanced lung cancer.
  • Presented data from two studies at the AACR 2009 Annual Meeting providing further confirmation of the unique immunomodulatory mechanisms contributing to the anti-tumor activity of Peregrine's anti-PS antibody platform.

    • Bavituximab Anti-Viral Program

    The company continued to advance the bavituximab anti-viral program:

    • Received major validation of the broad anti-viral potential of the company's anti-PS antib
      '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/16/2009)... SPRINGFIELD, Mass., Dec. 16 MassMutual,s Retirement ... new RetireSmart(SM) participant engagement platform in Q2 2010. ... of enrollment, transition and investment change materials in ... the option to choose from a menu of ... to their own participant population. The new RetireSmart ...
    (Date:12/16/2009)... (Boston) Boston University School of Medicine,s (BUSM) ... grant from the National Heart, Lung, and Blood ... from patients with lung disease. , Darrell ... and Gustavo Mostoslavsky, MD, PhD, assistant professor of ... grant award. Together Kotton and Mostoslavsky lead a ...
    (Date:12/16/2009)... staffing agency, is honored to announce that Chris Wepfer and ... the Year in Healthcare Traveler magazine’s 2009 Recruiters of the ... has received such honors and the first for Jackie. ... ... Medical Solutions, a national healthcare staffing agency, is honored to ...
    (Date:12/16/2009)... 16 Medizone International, Inc. (OTC Bulletin ... of Directors and the Board of Medizone New ... International Inc. holds a 50% interest, agreed on ... and reconvey to Medizone International all global marketing ... International,s Chairman, Edwin G. Marshall said, "Time has ...
    (Date:12/16/2009)... interval lessens complication risks , , TUESDAY, Dec. 15 (HealthDay News) ... such a profound impact on your life that you just ... new study suggests that you might want to wait at ... than 11 months could be even better. , The ... than six months, the chances of the baby dying, being ...
    Breaking Medicine News(10 mins):Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3
    ... Today, 1.1 billion people,lack access to safe water ... though many existing technologies and approaches can ensure ... In a report released,today, scientists and development experts ... and hygiene (WASH) sector. "The,good news is there ...
    ... Partner to, Combat Counterfeit Drugs, ALEXANDRIA, ... (NCPA), on the heels of the first annual,"Protect ... pharmacy robberies,and burglaries, has partnered with the United ... combat counterfeited and pirated,prescription drugs., "Counterfeit drugs ...
    ... WebMD Health Corp. (Nasdaq:,WBMD) and HLTH Corporation (Nasdaq: ... scheduled to participate at the Third Annual Needham & ... 2008 at 8:00 am ET., Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
    ... of brain tissue samples from chronic alcoholics reveals changes ... and suggests a potential treatment target, according to ... Reporting in Alcoholism: Clinical and Experimental Research, the scientists ... involved in cell signaling and development is found at ...
    ... Announces 2008,Journalistic Achievement Awards, NEW YORK, May ... Show are among winners receiving top honors,in the ... for Aesthetic Plastic Surgery (ASAPS). Selected from among ... their awards on May,6th, at ASAPS, Annual Meeting ...
    ... Pa., May 2 The Association for,Community Affiliated ... a,risky proposal by the State Department of Public ... many as one million Medicaid,enrollees in the Commonwealth., ... prescription drugs,away from the health plans and urge ...
    Other Medicine News:Health News:Improving Access to Safe Water, Sanitation, Hygiene Requires Better Decision-Making Tools, Finds Joint Wilson Center-Pacific Institute Report 2Health News:US Chamber of Commerce Joins 'Protect Your Pharmacy Now!' Initiative 2Health News:US Chamber of Commerce Joins 'Protect Your Pharmacy Now!' Initiative 3Health News:Analysis of alcoholics' brains suggests treatment target 2Health News:Aesthetic Society Awards Journalists' Commitment to Patient Education 2Health News:Aesthetic Society Awards Journalists' Commitment to Patient Education 3Health News:Pennsylvania Pharmacy 'Carve-out' Poses Risks for Commonwealth's Neediest Citizens and Taxpayers, National Organization Testifies 2
    (Date:12/16/2009)... Biovista Inc.,today announced that it was awarded the ... 2009 New England Venture Summit, held on December ... edge private companies,driving the future of innovation, was ... privately held companies that play a leading role ... sectors. , "We are ...
    (Date:12/16/2009)... PARSIPPANY, N.J. and ANN ARBOR, Mich., Dec. 16 ... GSK ) and NanoBio Corporation today announced an ... Canada for the over-the-counter (OTC) use of NB-001, ... in the treatment of cold sores. Developed by ... virus that causes cold sores, herpes labialis ...
    (Date:12/16/2009)... 16 MAQUET Cardiovascular LLC, a ... that it has signed a three-year single ... leading supply contracting company, for MAQUET,s market-leading ... VASOVIEW products assist healthcare providers in obtaining ... using only small incisions. This allows for ...
    Breaking Medicine Technology:Biovista Inc. Named Top Innovator in Life Sciences 2GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4FaxBack Awarded 26quot 3BBest of Show 26quot 3B at ITEXPO West 2009 57042 1FaxBack Awarded 26quot 3BBest of Show 26quot 3B at ITEXPO West 2009 57042 2FaxBack Awarded 26quot 3BBest of Show 26quot 3B at ITEXPO West 2009 57042 3Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER 28TM 29 Campaign Featuring Melissa Ethe 57038 1Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER 28TM 29 Campaign Featuring Melissa Ethe 57038 2Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER 28TM 29 Campaign Featuring Melissa Ethe 57038 3Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER 28TM 29 Campaign Featuring Melissa Ethe 57038 4Lilly Names New Business Leaders 57034 1Lilly Names New Business Leaders 57034 2Lilly Names New Business Leaders 57034 3Lilly Names New Business Leaders 57034 4Lilly Names New Business Leaders 57034 5Lilly Names New Business Leaders 57034 6Lilly Names New Business Leaders 57034 7Lilly Names New Business Leaders 57034 8
    ... THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros,Therapeutics ... month study of Proellex in the treatment of,endometriosis. ... and has completed six months of dosing. The,study ... as a,positive control arm. The positive control was ...
    ... 2007 - Neurogen,Corporation (Nasdaq: NRGN) today announced that ... the Company's lead compound,for the treatment of insomnia, ... of the Associated Professional Sleep Societies,(APSS) in Minneapolis, ... chronic insomnia patients are currently being,conducted by the ...
    Other Medicine Technology:Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 2Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 4Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 5Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 6Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4
    ... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
    ... TME 227 T is a ... temporary cardiac pacing and monitoring ... The TME 227 T features ... myocardium, which allows safe and ...
    For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
    For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
    Medicine Products: